ZHONGSHENGYAOYE(SZ:002317) Guotou Securities·2025-04-28 09:03Investment Rating - The report maintains a "Buy-A" investment rating for the company, with a 6-month target price of 17.01 CNY per share [5]. Core Views - The company reported a loss in 2024 due to asset impairment provisions totaling 547 million CNY, but is expected to enter a phase of recovery in 2025 with the potential for innovative drug launches [2][3]. - The company’s revenue for 2024 was 2.467 billion CNY, a decrease of 5.48% year-on-year, while the net profit attributable to shareholders was -299 million CNY, a decline of 213.63% [1][2]. - In Q1 2025, the company achieved a revenue of 634 million CNY, a slight decrease of 1.07% year-on-year, but net profit attributable to shareholders increased by 61.06% to 83 million CNY [1]. Financial Summary - The company is projected to achieve revenues of 2.853 billion CNY, 3.431 billion CNY, and 4.146 billion CNY for 2025, 2026, and 2027 respectively, with corresponding net profits of 302 million CNY, 460 million CNY, and 630 million CNY [4][10]. - The earnings per share (EPS) are expected to be 0.36 CNY, 0.54 CNY, and 0.74 CNY for the years 2025, 2026, and 2027, with price-to-earnings (PE) ratios of 31.6, 20.7, and 15.1 respectively [4][10]. - The company’s total market capitalization is approximately 9.563 billion CNY, with a circulating market capitalization of about 8.553 billion CNY [5].